AVDL Avadel Pharmaceuticals plc

1.15
-0.02  -2%
Previous Close 1.17
Open 1.18
Price To Book 16.43
Market Cap 42563816
Shares 37,012,014
Volume 126,883
Short Ratio
Av. Daily Volume 164,199

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery
Announced approval May 2 2016
Akovaz
Hypotension
Phase 3 SPA agreed on - October 2016. Initiation of dosing announced December 16, 2016.
FT 218
Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy
Approved June 30 2014.
VAZCULEP (phenylephrine hydrochloride)
Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia
Approved Jun 3 2013
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery

Latest News

  1. Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
  2. Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
  3. Avadel: 4Q Earnings Snapshot
  4. Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  5. Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
  6. Avadel Pharmaceuticals Clarifies Announcement of Corporate Restructuring
  7. [$$] Avadel Specialty Pharmaceuticals Files for Chapter 11 Bankruptcy
  8. Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program
  9. ‘Sleep Normal’ campaign urges Americans to end frequent nighttime urination and stop settling for nights of bad sleep
  10. Read This Before Selling Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares
  11. Avadel Pharmaceuticals Announces Changes to Management Team and Board of Directors
  12. Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA
  13. Avadel Pharmaceuticals Appoints Kevin Kotler to the Company’s Board of Directors
  14. Report: Developing Opportunities within Eaton Vance, IDT, Hemispherx BioPharma, Edgewell Personal Care, Rockwell Medical, and Avadel Pharmaceuticals — Future Expectations, Projections Moving into 2018
  15. As Waking Up Multiple Times a Night to Urinate Can Lead to Memory Deficits, Obesity, Lowered Sex Drive, Falls and Depression, a New Council Urges Awareness and Action
  16. Avadel Pharmaceuticals Reports Third Quarter 2018 Financial Results